For a world without autoimmune diseases
Targeted Active Therapies and
Active Targeted Immunotherapies
Who we are
CuraVac is a clinical-stage biotechnology company developing Targeted Active Therapy and Active Targeted Immunotherapies for autoimmune diseases.
With the use of a new revolutionary technique based on complementary peptides, we aim to treat and to induce long-term immunity against autoimmune diseases such as Multiple Sclerosis (MS), Myasthenia Gravis (MG), Type 1 diabetes, Graves’ disease, Systemic Lupus Erythematosus (SLE) and Hashimoto’s disease.
CuraVac’s CV-MG is a potential breakthrough in MG treatments and a potential therapeutic revolution for all autoimmune diseases – being the first to possibly bring a long-lasting improvement and a potential cure to patients.
Autoimmune diseases in the U.S.
The CuraVac team is composed of 8 key people at the center of a collaborative network of the highest quality from the industry and the academic world: Dr. Stéphane Huberty, Nicolas Havelange, Dr. Jean-Paul Prieels, Leone Flynn, Alexandra Deschner, Samuel Osumba, Dimitri Dimitriou and Matthieu André.
Dr. Stéphane Huberty
Founder and Chief Executive Officer
Nicolas Havelange
Chief Operating Officer
Dr. Jean-Paul Prieels, Ph.D.
Chief Scientific Officer
Leone Flynn
CAO
Alexandra Deschner
Investor Relations Advisor
Samuel Osumba
Project manager
Dimitri F. Dimitriou
Executive Chairman of the Board
Matthieu André
Chief Financial Officer
Our Independent Advisory Board is composed of key specialists from the industry and the academic world who provide the management team with valuable input in its strategic decision making.
Dr. Melanie Lee, PhD
Dr. Melanie Lee is a former CEO of LifeArc, a UK-based medical research charity focused on translating innovative new science into products and solutions for patients.
Dr. Didier Hoch, M.D.
CEO of BIOVISION and the World Life Sciences Forum. He is a medical doctor and has more than 25 years of experience in the pharmaceutical and vaccine industries.
Professor J. Edwin Blalock, PhD
Professor Blalock is a renowned scientist with more than 300 scientific publications in top ranked peer reviewed scientific journals and whose work has been funded all through out his career.
Prof. Shigeru Araga, MD, PhD
He is a Medical Doctor, board certified neurologist in Japan, Associate Professor in Neurology at the Tottori University School of Medicine and former Director of the Fujii Memorial Hospital.
Dr. Bruce Forrest, M.D., MBA
Dr. Forrest has over 25 years of global leadership in pharmaceutical development with specialty expertise in vaccines and biopharmaceuticals development.
Dr. Eddy Rommel, DVM, MS
Dr. Eddy Rommel has over 35 years of experience in animal research, vaccine quality control, and non-clinical development of biopharmaceuticals.
Foundation
CuraVac was founded in 2002 by Dr. Stéphane Huberty, a Belgian medical doctor who suffered from Myasthenia Gravis. Soon after, the company acquired the complementary peptide patent, raised funds and got organized as a management company at the center of a network of collaborations and sub-contracting companies. The original discoverer of the Active Targeted Immunotherapy technology, Professor J. Edwin Blalock also joined CuraVac as a consultant.
Present day
Following a Clinical Trial Authorization received in November 2015, 24 patients received three injections of the MG Targeted Active Therapy in a phase 1B clinical trial that took place at the Antwerp University hospital (UZA) in Belgium. The preliminary results were communicated in May 2017 at the 13th International Conference on Myasthenia Gravis and Related Disorders at the New York Academy of Science.
The final results of phase 1B, communicated in June 2018, demonstrated an excellent safety profile and called for a phase 2 efficacy clinical trial.
CuraVac is presently preparing a phase 2 efficacy clinical trial with an improved and more potent formulation of the MG Targeted Active Therapy: CV-MG02.
- In 2009, the human formulation of the MG vaccine is manufactured following GLP and GMP guidelines.
The myasthenia gravis Targeted Active Therapy, our first therapy, was granted Orphan Drug Designation in Europe by a team of independent experts of the 27 European member states.
- In 2011, the MG Targeted Active Therapy was granted Orphan Drug Designation in the USA by the FDA
They didn’t know it was impossible so they did it
— Mark Twain
Wish to ask us about our progress, our platform, share your story or anything else?
You can send us an email at info@curavac.com or simply submit the form here.
